FN2 Earnings Intelligence
Boston Scientific Corporation ratios (quarterly)
Boston Scientific Corporation (BSX) Ratios (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 est. | 9/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $2,502 | $725 | $534 | $1,275 | $1,453 | - | - |
| + Debt | $12,576 | $12,020 | $11,799 | $11,809 | $10,976 | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $4,209 | $4,663 | $5,061 | $5,065 | $5,203 | $5,364.9 | $5,379.6 |
| % Growth | - | - | - | - | - | 6.0% | 6.2% |
| Gross Profit | $2,897 | $3,210 | $3,424 | $3,542 | $3,614 | - | - |
| % Margin | 68.8% | 68.8% | 67.7% | 69.9% | 69.5% | - | - |
| EBITDA | $835 | $1,246 | $930 | $1,165 | $1,452 | - | - |
| % Margin | 19.8% | 26.7% | 18.4% | 23.0% | 27.9% | - | - |
| Net Income | $468 | $672 | $795 | $755 | $1,339 | - | - |
| % Margin | 11.1% | 14.4% | 15.7% | 14.9% | 25.7% | - | - |
| Diluted EPS | $0.32 | $0.45 | $0.53 | $0.51 | $0.90 | $0.83 | $0.84 |
| % Growth | - | - | - | - | - | 56.2% | 64.2% |
| Operating Cash Flow | - | $541 | - | - | $348 | - | - |
| CapEx | - | $187 | - | - | $177 | - | - |
| Free Cash Flow | - | $354 | - | - | $171 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 est. | 9/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $4,209 | $4,663 | $5,061 | $5,065 | $5,203 | $5,364.9 | $5,379.6 |
| Gross Profit | $2,897 | $3,210 | $3,424 | $3,542 | $3,614 | - | - |
| EBITDA | $835 | $1,246 | $930 | $1,165 | $1,452 | - | - |
| Net Income | $468 | $672 | $795 | $755 | $1,339 | - | - |
| Diluted EPS | $0.32 | $0.45 | $0.53 | $0.51 | $0.90 | $0.83 | $0.84 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $2,502 | $725 | $534 | $1,275 | $1,453 |
| Short-term Debt | $1,652 | $777 | $480 | $483 | $41 |
| Long-term Debt | $10,924 | $11,243 | $11,319 | $11,326 | $10,935 |
| Total Debt | $12,576 | $12,020 | $11,799 | $11,809 | $10,976 |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | $541 | - | - | $348 |
| Capital Expenditure | - | $187 | - | - | $177 |
| Free Cash Flow | - | $354 | - | - | $171 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 68.8% | 68.8% | 67.7% | 69.9% | 69.5% |
| EBITDA Margin | 19.8% | 26.7% | 18.4% | 23.0% | 27.9% |
| Net Margin | 11.1% | 14.4% | 15.7% | 14.9% | 25.7% |
| FCF Margin | - | 7.6% | - | - | 3.3% |
| Diluted EPS Growth | - | - | - | - | - |